Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Endometrial Serous Adenocarcinoma: early-phase trial registry
3 of 13 indexed Endometrial Serous Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 3 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Endometrial Serous Adenocarcinoma: 13 US clinical trials tracked, 3 recruiting.
Endometrial Serous Adenocarcinoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
Enrollment posture brief
Registry condition endometrial-serous-adenocarcinoma
OPEN 3 | RECR 23% | LATE 3 | EARLY 7 | RANK #1315 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Infant, Small for Gestational Age (23% recruiting · 13 trials)
Endometrial Serous Adenocarcinoma lists 3 open slots (23% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Endometrial Serous Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Endometrial Serous Adenocarcinoma is recruiting below its size-band peers.
3 of 13 indexed trials (23.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Endometrial Serous Adenocarcinoma research.
National Cancer Institute (NCI) accounts for 8 of 13 trials (61.5%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Endometrial Serous Adenocarcinoma enrolment sits around 188 participants.
Median target enrolment is 188 among the 13 trials that report a genuine target (sentinel values excluded). 5 of those (38.5%) plan for fewer than 100 participants.
-
Endometrial Serous Adenocarcinoma research is mostly interventional.
11 interventional and 2 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
M.D. Anderson Cancer Center
NCT05049538
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
NCT05256225
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
University of Utah
NCT03422198
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT03914612
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT00977574
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
NCT03660826
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
M.D. Anderson Cancer Center
NCT01737619
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02142803
Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy
National Cancer Institute (NCI)
NCT04494113
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
Gynecologic Oncology Group
NCT01344837
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
National Cancer Institute (NCI)
NCT01307631
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Gynecologic Oncology Group
NCT01225887
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
NCT01935973
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Endometrial Serous Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Endometrial Serous Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Endometrial Serous Adenocarcinoma page
13 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Endometrial Serous Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Endometrial Serous Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Serous Adenocarcinoma condition card totals 13 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.